Sign In
Buy RGEN
$121.73
+0.600 (+0.495%)
At Close: Jun 03, 2026
Repligen Beats on Q3 Earnings & Sales, Narrows '24 Sales View
02:40pm, Tuesday, 12'th Nov 2024
RGEN reports better-than-expected third-quarter results. While management lowers its guidance for 2024 total sales, it raises the same for EPS.
Repligen Q3 Earnings Beat Expectations, Highlights Improving Market Conditions, Analyst Says Well-Positioned For Long-Term Growth
01:19pm, Tuesday, 12'th Nov 2024
Repligen Corp RGEN released on Tuesday third-quarter adjusted EPS of 43 cents, up from 23 cents a year ago, beating the consensus of 33 cents.
Repligen (RGEN) Q3 Earnings and Revenues Beat Estimates
10:05am, Tuesday, 12'th Nov 2024
Repligen (RGEN) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.23 per share a year ago.
Repligen Corporation's Earnings Preview: Expensive With Mixed Growth Prospects
06:36am, Tuesday, 12'th Nov 2024
Repligen Corporation is a bioprocessing technology company focusing on process intensification, purification, and fluid management, with strategic acquisitions to enhance its capabilities. Though inte
Repligen Corporation to Present at Upcoming Investor Conferences
07:30am, Tuesday, 05'th Nov 2024
WALTHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting
Repligen (RGEN) Earnings Expected to Grow: What to Know Ahead of Q3 Release
11:05am, Tuesday, 22'nd Oct 2024
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dublin, Oct. 14, 2024 (GLOBE NEWSWIRE) -- The "Peptide Therapeutics - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Peptide Therapeutics
Repligen Opens Training & Innovation Center to Elevate Customer Experience
07:30am, Tuesday, 24'th Sep 2024
WALTHAM, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the grand opening of its
Repligen Corporation to Present at Wells Fargo Healthcare Conference
07:30am, Friday, 23'rd Aug 2024
WALTHAM, Mass., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting
Exclusive: Repligen in bid for reagent vendor Maravai, sources say
11:46am, Friday, 16'th Aug 2024
Repligen , a provider of drug manufacturing equipment, has approached Maravai LifeSciences Holdings , a vaccine capping reagent vendor that has a market value of $2.2 billion, with an acquisition offe
Here's Why Shares in This Hot Healthcare Stock Surged This Week
07:09am, Friday, 02'nd Aug 2024
A far larger peer backs up Repligen's market commentary. Bioprocessing customers are working through inventory, and orders growth is bouncing back.
These Analysts Revise Their Forecasts On Repligen Following Q2 Results
02:50pm, Wednesday, 31'st Jul 2024
Repligen Corporation RGEN reported in-line earnings for its second quarter on Tuesday.
Repligen's (RGEN) Q2 Earnings & Revenues Meet Estimates
11:51am, Wednesday, 31'st Jul 2024
Repligen's (RGEN) second-quarter earnings and revenues match estimates. The company narrows its revenue guidance for 2024.
Repligen Corporation (RGEN) Q2 2024 Earnings Call Transcript
03:03pm, Tuesday, 30'th Jul 2024
Repligen Corporation [RGEN] Q2 2024 Earnings Conference Call July 30, 2024 8:30 AM ET Company Participants Tony Hunt - CEO Jason Garland - CFO Olivier Loeillot - President & CCO Sondra Newman - IR Con
Repligen Lowers Guidance On China Weakness, Analyst Expects
12:01pm, Tuesday, 30'th Jul 2024
Tuesday, Repligen Corporation RGEN reported second-quarter sales of $154.1 million, almost in line with the consensus estimate of $154.12 million.
